Anthrax Company

NPR's Steve Inskeep reports on BioPort, the only company holding a contract to produce a vaccine for anthrax. The company is in financial trouble, and it appears unlikely it will be able to meet the Defense Department demand for millions of doses of the vaccine, used to protect U.S. service personnel from the possibility of biological warfare.

Comments

 

Please keep your community civil. All comments must follow the NPR.org Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.